Сравнение на методи
Прегледайте избраните методи един до друг; редовете с разлики са откроени.
| Анализ на въздействието върху бюджета (BIA)× | Година коригирана по качество на живота (QALY)× | |
|---|---|---|
| Област | Икономика на здравеопазването | Икономика на здравеопазването |
| Семейство | Process / pipeline | Process / pipeline |
| Година на възникване≠ | 2005 | 1985 |
| Създател≠ | Sullivan, Mauskopf, and colleagues (ISPOR task force) | Alan Williams (Health Economics Research Centre, Oxford University) |
| Тип | Method | Method |
| Основополагащ източник≠ | Sullivan, S. D., Mauskopf, J. A., Augustovski, F., et al. (2014). Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health, 17(1), 5-14. DOI ↗ | Kind, P. (1989). The EuroQol instrument: an index of health-related quality of life. In B. Teeling Smith (Ed.), Measuring health: a practical approach. Chichester: Wiley. link ↗ |
| Други названия≠ | BIA, financial impact assessment, budget consequence analysis | QALY, health utility measure |
| Свързани | 5 | 5 |
| Резюме≠ | Budget impact analysis estimates the financial consequences (net costs or savings) of implementing a new health technology in a specific healthcare system or population over a short time horizon (typically 1–5 years). Distinct from cost-effectiveness analysis (which compares health outcomes per dollar), BIA answers a budgetary question: 'If we adopt this new drug/device, how much will it cost our health system next year?' Widely used by hospital procurement committees, insurance formularies, and government health budgets to assess financial feasibility and reimbursement decision. | A QALY measures health benefit as utility weight (0 = death, 1 = perfect health) multiplied by time lived. Developed by Alan Williams in 1985, QALYs enable comparison of disparate health interventions on a common metric. Used globally by health technology assessment bodies—NICE (UK), HAS (France), CADTH (Canada), WHO—to decide which treatments deserve public funding. |
| ScholarGateНабор от данни ↗ |
|
|